ASSET PURCHASE AGREEMENT by and between NABI BIOPHARMACEUTICALS and GLAXOSMITHKLINE BIOLOGICALS S.A. Dated as of August 5, 2009Asset Purchase Agreement • November 5th, 2009 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of August 5, 2009 (the “Execution Date”), is entered into by and between NABI BIOPHARMACEUTICALS, a Delaware corporation with offices at 12276 Wilkins Avenue Rockville, MD 20852 USA (“Seller”), and GLAXOSMITHKLINE BIOLOGICALS S.A., a Belgium corporation with offices at Rue de l’Institut 89, 1330 Rixensart, Belgium (“Buyer”). Seller and Buyer are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.” All capitalized terms used herein, including in the Exhibits and Schedules hereto, shall have the meanings specified in ARTICLE I or elsewhere in this Agreement, as applicable, unless otherwise specified.
CONSULTING AGREEMENTConsulting Agreement • November 5th, 2009 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • Maryland
THIS CONSULTING AGREEMENT (the “Agreement”) is effective as of the date first written above (the “Effective Date”), between Nabi Biopharmaceuticals, a Delaware corporation, having a place of business at 12276 Wilkins Avenue, Rockville, Maryland 20852 (the “Company”) and Linda Jenckes & Associates, with an office at 1201 Pennsylvania Ave., NW Suite 500, Washington, DC 20004, (the “Consultant”). For purposes of this Agreement, the term “Consultant” will apply to the person or entity named above as well as to the personnel employed by such person or entity, if any. Also, for purposes of this Agreement, the “Effective Date” will be the “Start Date” unless otherwise stated in the attached Schedule.
